Modiodal (Modafinil)

• Modiodal (modafinil) is prescribed for several sleep‑wake disorders where excessive daytime sleepiness is a primary symptom.
• Narcolepsy: reduces the frequency of daytime sleep attacks, improves overall alertness, and supports better daily functioning in affected individuals.
• Obstructive sleep apnea‑related excessive daytime sleepiness: enhances wakefulness and reduces sleepiness when used as an adjunct to standard continuous positive airway pressure (CPAP) therapy.
• Shift work sleep disorder: helps maintain alertness and cognitive performance during scheduled work hours that conflict with the normal circadian rhythm, facilitating safer and more productive night‑time work.

• Modafinil promotes wakefulness primarily by inhibiting the reuptake of dopamine, thereby increasing extracellular dopamine concentrations in brain regions that regulate arousal. It also modulates additional neurotransmitter systems, including orexin, histamine, norepinephrine and serotonin pathways, which together enhance cortical activation and reduce sleep propensity. The drug’s effect on these systems is thought to increase glutamatergic transmission while decreasing GABAergic inhibition, contributing to a net excitatory state that supports sustained alertness without directly stimulating adrenergic receptors.

Modiodal may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

• Headache
• Nausea
• Insomnia
• Dry mouth

Serious or Rare Side Effects

• Rash or Stevens‑Johnson syndrome
• Psychiatric symptoms such as mania or hallucinations
• Cardiac arrhythmia

• Before initiating therapy, clinicians should consider several safety measures.
• Cardiovascular assessment: evaluate blood pressure and heart rhythm in patients with known cardiac disease.
• Psychiatric history review: avoid use in individuals with uncontrolled psychosis or severe anxiety.
• Concomitant medication review: assess for drugs that affect CYP3A4 metabolism.
• Liver function monitoring: periodic testing is advised for patients with hepatic impairment.
• Avoid use in known hypersensitivity: discontinue if allergic reaction occurs.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Modiodal can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) – may increase plasma concentrations.
• Hormonal contraceptives – may reduce contraceptive efficacy.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine) – may lower drug exposure.
• Antihypertensives – may enhance blood‑pressure‑lowering effect.
• Alcohol – can increase central nervous system side effects.
• Caffeine – may exacerbate insomnia or nervousness.